MARKET

EYPT

EYPT

EyePoint
NASDAQ
17.08
-0.29
-1.67%
After Hours: 17.08 0 0.00% 17:36 01/08 EST
OPEN
17.50
PREV CLOSE
17.37
HIGH
17.74
LOW
16.94
VOLUME
746.89K
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
3.910
MARKET CAP
1.41B
P/E (TTM)
-5.7131
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and ANI Pharmaceuticals (ANIP)
TipRanks · 18h ago
EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target
TipRanks · 21h ago
Top Executive Makes Major Move With EyePoint Pharmaceuticals Stock
TipRanks · 1d ago
EyePoint Inc. Chief Medical Officer Ramiro Ribeiro Reports Disposal of Common Shares
Reuters · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alphatec Holdings (ATEC) and EyePoint Pharmaceuticals (EYPT)
TipRanks · 1d ago
Highlights 2026 Milestones; Says Pivotal Phase 3 Trials In Wet AMD On Track For Data Readout Beginning In Mid-2026; Phase 3 DME Program First Patient Dosing Expected In Q1 2026
Benzinga · 1d ago
EyePoint reports corporate update, 2026 anticipated milestones for DURAVYU
TipRanks · 1d ago
EyePoint Inc. to Present at J.P. Morgan Healthcare Conference
Reuters · 1d ago
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.